In addition, many reports have also shown that GLP-1 signaling displays a positive effect in terms of increasing insulin sensitivity [25], which can also help to explain the possible mechanism whereby Liraglutide promotes the protection or effect of SCs, and thus provides a possible strategy for increasing the efficacy of future treatments of DN. The gene discussed is GLP1R; the disease is liver dysplastic nodule.